Navigation Links
EmergingMed Granted Patent
Date:6/3/2010

NEW YORK, June 3 /PRNewswire/ -- The U.S. Patent Office issued Patent No. 7,711,580, A System and Method for Matching Patients With Clinical Trials, to EmergingMed on May 4, 2010.

The patent covers a system and method for matching patients with clinical trials and particular trial sites, prequalifying patients for clinical trials and trial sites, and providing information to patients to allow them to inform themselves about available clinical trials and trial sites.

"The growth of targeted therapies as well as molecular diagnostics and gene expression profiling raises the complexity of finding clinical trials and personalized health information quickly, accurately, and confidentially," says Dr. Karen Moffitt of Florida Cancer Trials.  "EmergingMed's system simultaneously solves this problem for Florida's physicians and investigators, and most importantly our patients."

"AstraZeneca understands how challenging it can be for a patient or caregiver to navigate the multitude of information sources that exist for oncology clinical trials, let alone to identify trials that may be an appropriate match for themselves or a loved one," said Edward Mannello, Director of Clinical Study Recruitment, AstraZeneca. "For that reason, AstraZeneca has collaborated with EmergingMed because of the unique service they can provide to patients--a customized tool that helps them find trials that may be best matched to their specific needs."

"LIVESTRONG is proud to partner with EmergingMed on our SurvivorCare program," added Andy Miller, Executive Vice President of Mission for the Lance Armstrong Foundation.  "EmergingMed is instrumental in providing comprehensive support to people affected by cancer through their unique clinical trials education and matching program, their commitment to the cancer community, and their ability to respond to the needs of those affected by cancer."  

EmergingMed's phone and web-based matching system is featured by more than 50 patient advocacy organizations, pharmaceutical and biotech companies, and medical centers including Lance Armstrong Foundation, Pfizer, Genentech, AstraZeneca, EMD Serono, Enzon, CarisMPI, Ohio State University, the State of Florida, and POETIC.

"Trial sponsors and research sites utilize EmergingMed's customized solutions to find targeted patient populations, to ensure routine prescreening of all patients, and to analyze the suitability of their clinical trials for their specific patient populations," added Courtney Hudson, CEO.  "Our long-term follow-up with patients allows us to track outcomes, identify barriers, and empower patients to consider clinical trials each time a treatment decision is needed."  

EmergingMed said that although it will vigorously protect its intellectual property rights, it is seeking to broadly distribute its matching services beyond oncology to include other disease areas.

About EmergingMed

EmergingMed provides personalized clinical trial matching, referral support, education and long-term follow-up with patients on behalf of patient advocacy organizations, medical centers, pharmaceutical & biotech companies, and the State of Florida. Founded in 2000, EmergingMed has offices in New York, NY and Durham, NC.   For more information, call 1-877-601-8601 ext. 230 or write to EColeman@emergingmed.com.


'/>"/>
SOURCE EmergingMed
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
3. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
4. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
5. ISTO Technologies Granted Key Patent for Cartilage Cell Expansion by the United States Patent Office
6. Odyssey Thera Granted U.S. Patent for Animal Imaging
7. Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
8. Kiwa Bio-Tech New Bio-Fertilizer Product Granted Initial Fertilizer Registration Certificate By Ministry of Agriculture of the PRC
9. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
10. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
11. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- NX Prenatal Inc., a US based molecular ... early warning of adverse pregnancy outcomes, announced today ... Dr. Thomas McElrath of Brigham & ... (SMFM) annual meeting held in Atlanta ... presentation reported initial positive top-line results regarding the ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... announced that it has joined the Human Vaccines Project, a public-private partnership ... and cancer. , The Human Vaccines Project brings together leading pharmaceutical ...
(Date:2/10/2016)... , Feb. 10, 2016  Allergan plc (NYSE: ... announced that Brent Saunders , Allergan,s CEO and ... a fireside chat session at the RBC Capital Markets ... p.m. ET at The New York Palace Hotel in ... will be webcast live and can be accessed on ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... three states, announced today the promotion of two long-standing principal investigators (PI) to ... Family Medicine, Clinical Research and Development. , Dr. Laurence Chu, a Benchmark Research ...
Breaking Biology Technology:
(Date:2/3/2016)... DUBLIN , Feb. 3, 2016 /PRNewswire/ ... announced the addition of the "Emotion ... NLP, Machine Learning, and Others), Software Tools ... Application Areas, End Users,and Regions - Global ... offering. --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) ...
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/2/2016)... 2016  Based on its recent analysis of ... US-based Intelligent Retinal Imaging Systems (IRIS) with the ... New Product Innovation. IRIS, a prominent cloud-based retinal ... , is poised to set the new ... market. The IRIS technology presents superior price-performance value ...
Breaking Biology News(10 mins):